SGMC Health in Valdosta, Georgia, has begun offering lecanemab, an FDA-approved monoclonal antibody, to patients with early-stage Alzheimer’s disease, targeting amyloid-beta plaques to potentially sluggish cognitive decline by up to 27% over 18 months in eligible individuals with mild cognitive impairment or mild dementia due to Alzheimer’s pathology.
How Lecanemab Targets Alzheimer’s Pathology at the Molecular Level
Lecanemab (Leqembi) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to bind selectively to soluble amyloid-beta protofibrils, which are neurotoxic intermediates in the amyloid cascade hypothesis of Alzheimer’s disease. By neutralizing these protofibrils before they form insoluble plaques, lecanemab aims to disrupt a key upstream driver of neurodegeneration, synaptic dysfunction, and neuroinflammation. This mechanism differs from earlier anti-amyloid agents like aducanumab, which primarily target fibrillary plaques, potentially explaining lecanemab’s stronger signal on cognitive endpoints in Phase III trials. The drug is administered via intravenous infusion every two weeks, requiring sustained access to infusion centers and monitoring for amyloid-related imaging abnormalities (ARIA), a known class effect involving transient brain swelling or microhemorrhages detectable on MRI.
In Plain English: The Clinical Takeaway
- Lecanemab is not a cure but may slow memory and thinking decline in early Alzheimer’s when given early, and consistently.
- Treatment requires biweekly IV infusions and regular brain scans to monitor for rare but serious side effects like brain swelling or bleeding.
- Only patients confirmed to have amyloid-beta plaques via PET scan or spinal fluid test are eligible, ruling out other causes of dementia.
Clinical Efficacy, Trial Design, and Real-World Accessibility
The approval of lecanemab was grounded in the Phase III Clarity AD trial (NCT03887455), a randomized, double-blind, placebo-controlled study involving 1,795 participants aged 50–90 with early Alzheimer’s disease confirmed by amyloid PET or cerebrospinal fluid biomarkers. Over 18 months, lecanemab reduced cognitive decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale by 0.45 points compared to placebo, representing a 27% slowing of progression. Secondary endpoints showed significant reduction in amyloid burden on PET imaging. However, 12.6% of lecanemab recipients experienced ARIA-E (edema) and 17.3% ARIA-H (hemosiderin deposition), though most were asymptomatic and resolved with dosing adjustments. Two deaths in the treatment arm were attributed to ARIA complications, prompting enhanced screening protocols.
Geographically, access remains uneven. While the FDA granted traditional approval in July 2023 and the EMA recommended approval in early 2024, reimbursement policies vary. In the U.S., Medicare covers lecanemab for patients enrolled in approved registries or clinical trials, creating administrative barriers. In the UK, NICE has not yet recommended routine use within the NHS due to cost-effectiveness concerns, limiting availability to private patients. In contrast, Georgia’s SGMC Health, serving a predominantly rural population in the southeastern U.S., has integrated lecanemab into its neurology clinic workflow, offering biomarker testing via CSF analysis and coordinating infusions through its outpatient infusion center—addressing a critical gap in underserved regions where academic medical centers are distant.
Contraindications & When to Consult a Doctor
- Lecanemab is contraindicated in patients with active anticoagulant use, recent stroke, or uncontrolled hypertension due to heightened ARIA risk.
- Individuals with ApoE4 homozygosity face significantly higher ARIA incidence and should undergo genetic counseling prior to initiation.
- Patients should seek immediate medical attention for new-onset confusion, seizures, difficulty walking, or persistent headaches—potential signs of ARIA requiring urgent MRI evaluation.
- Those with severe renal or hepatic impairment, or a history of severe hypersensitivity to murine proteins, should avoid treatment.
Funding, Conflicts, and Independent Validation
The Clarity AD trial was funded by Eisai Co., Ltd. And Biogen Inc., the co-developers of lecanemab. While industry sponsorship is standard in late-stage drug development, independent validation has emerged: a 2024 meta-analysis in JAMA Neurology confirmed consistent efficacy across subgroups, and an observational study from the Kaiser Permanente Northern California cohort (published in Neurology, 2025) reported real-world adherence and safety patterns mirroring trial data. Transparency initiatives, including public sharing of trial protocols and open-access publication of primary results, have bolstered credibility despite inherent conflicts of interest.
“Lecanemab represents a meaningful advance—not because it halts Alzheimer’s, but because it provides the first disease-modifying therapy with clear clinical benefit in early stages. The challenge now is equitable delivery, biomarker access, and managing ARIA risk in community settings.”
— Dr. Reisa Sperling, Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, Harvard Medical School, speaking at the 2024 Alzheimer’s Association International Conference (AAIC).
Long-Term Outlook and Public Health Implications
While lecanemab’s effect size is modest, its approval marks a paradigm shift from symptomatic treatment to disease modification in Alzheimer’s care. Long-term data from the open-label extension of Clarity AD (expected 2026) will clarify whether sustained treatment delays progression to severe dementia or institutionalization. Public health models suggest that even a 25% slowing of progression, if applied broadly to the estimated 6.7 million Americans with Alzheimer’s, could reduce national caregiving burden by hundreds of thousands of years annually. However, realizing this potential requires investment in diagnostic infrastructure, workforce training, and equitable access—particularly in regions like the American South, where Alzheimer’s prevalence is highest but neurology resources are sparse. SGMC Health’s initiative exemplifies how community hospitals can bridge this gap when supported by state-level neurology networks and telemedicine consults with academic centers.
References
- van Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388:9-21. Doi:10.1056/NEJMoa2212948.
- Cummings J, et al. Safety and efficacy of lecanemab in early Alzheimer’s disease: Phase 3 randomized clinical trial. Alzheimers Res Ther. 2023;15:124. Doi:10.1186/s13195-023-01225-6.
- Salloway S, et al. Two years of lecanemab in early Alzheimer’s disease: results from the open-label extension of Clarity AD. Presented at AAIC 2024.
- Rabinovici GD, et al. Association of amyloid PET with Alzheimer’s disease clinical phenotypes. JAMA Neurol. 2019;76:992-1000. Doi:10.1001/jamaneurol.2019.1848.
- Sperling RA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups. Alzheimers Dement. 2011;7:280-292. Doi:10.1016/j.jalz.2011.03.003.
